EntryPoint Capital’s Stoke Therapeutics STOK Stock Holding History

EntryPoint Capital’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31,968	Closed	-$353K	–	937
2024 Q4	$353K	Buy	+31,968	New	+$393K	0.15%	276

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's STOK Position: Q1 2025 in Review

EntryPoint Capital sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 31,968 shares — an estimated $353K sold.

EntryPoint Capital first reported a position in STOK in Q4 2024 and held it in 1 quarter. The position peaked at $353K in Q4 2024. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

EntryPoint Capital reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 31,968 Stoke Therapeutics shares in Q1 2025, an estimated $353K.
EntryPoint Capital first reported a position in Stoke Therapeutics in Q4 2024 and held it in 1 quarter.
EntryPoint Capital's Stoke Therapeutics position peaked at $353K in Q4 2024.
126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.